# OnCo record excalipoint-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/excalipoint-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "excalipoint-therapeutics" ;
  schema:name "Excalipoint Therapeutics"@en ;
  schema:alternateName "Excalipoint Therapeutics Inc."@en ;
  schema:description "Excalipoint Therapeutics develops three-armed antibodies that attach immune T cells to solid-tumour cells and switch them on more fully. Its lead medicine, aimed at the protein DLL3 on small cell lung cancer and neuroendocrine tumours, is in an early clinical trial."@en ;
  schema:url <https://onco.cc/companies/excalipoint-therapeutics/>, <https://www.excalipoint.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.excalipoint.com/>, <https://www.biopharmadive.com/news/excalipoint-biotech-startup-china-t-cell-engagers/814829/> ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/neuroendocrine/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/trispecific-antibodies/> ;
  onco:targets <https://onco.cc/targets/dll3/> .